5-Amino-1MQ
5-Amino-1MQ is a wildly powerful, game-changing small-molecule metabolic engine designed to violently disrupt fat storage at the cellular level. By explicitly targeting the NNMT (Nicotinamide N-methyltransferase) enzyme—which is notoriously over-expressed in obese tissue—it single-handedly reverses diet-induced metabolic slowdown. Functioning as a potent oral biohacker's tool, it forces a massive, relentless surge in the Basal Metabolic Rate (BMR) and fundamentally shrinks adipocytes (fat cells), aggressively driving extreme, sustained weight loss without the jittery, nervous-system-wrecking side effects of traditional stimulants.
Quick Stats
Scientific Data
Mechanism of Action
5-Amino-1MQ (5-Amino-1-methylquinolinium) is a cell-permeable small molecule that selectively inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide — diverting SAM (S-adenosylmethionine) and depleting cellular NAD+ precursor pools.
NNMT is overexpressed in obesity, type 2 diabetes, and aged adipose tissue. By inhibiting NNMT, 5-Amino-1MQ raises NAD+ levels, activates SIRT1 (the longevity sirtuin), and promotes a lean metabolic phenotype. In preclinical studies, it prevented diet-induced obesity without reducing food intake, and preserved muscle mass. It represents a distinct mechanism from NMN/NR supplementation — instead of directly adding NAD+ precursors, it stops NAD+ from being wasted.
Source: PMID: 31028097
Background & History
5-Amino-1MQ (5-Amino-1-methylquinolinium) is a small-molecule cell-permeable inhibitor of nicotinamide N-methyltransferase (NNMT) developed by researchers at Vanderbilt University. NNMT is an enzyme expressed primarily in fat tissue that consumes S-adenosylmethionine (SAM) to methylate nicotinamide — effectively diverting NAD+ precursors away from energy metabolism. First published in Nature Communications (2018), 5-Amino-1MQ demonstrated that NNMT inhibition in obese mice prevented weight gain without caloric restriction. It has since exploded in biohacking communities as a novel oral compound for metabolic optimization and fat loss.
Research Use Cases
- ✓Metabolic optimization: fat loss without caloric restriction (preclinical)
- ✓NAD+ restoration and longevity via NNMT pathway
- ✓Skeletal muscle energy metabolism and AMPK activation
- ✓Prevention of obesity-associated adipogenesis
- ✓Companion to NAD+ IV therapy or NMN for comprehensive NAD+ optimization
Dosing Protocol
| Typical Dose | 50-100 mg/day (oral) |
| Frequency | 1× daily (oral) |
| Half-Life | ~4-6 hours (estimated) |
Dosing Protocols
Research Protocol (Oral)
Administration
Expected Timeline
Who Is It For?
NAD+ Optimization
LowNovel NNMT inhibition mechanism raises NAD+ by stopping its depletion. Complementary to NMN/NR supplementation.
Obesity / Metabolic Health
LowPreclinical data shows prevention of diet-induced obesity. No human RCTs yet.
Safety & Considerations
Research compound. Limited human safety data. Preclinical studies show favorable safety profile. Avoid in pregnancy. Monitor liver enzymes with extended use. Not combined with MAOIs.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
Very limited human safety data — primarily mouse studies. NNMT inhibition affects SAM methylation metabolism; theoretically could affect methylation of other substrates (neurotransmitters, DNA). Avoid with MAOI medications. Monitor liver enzymes during use. Not approved for human use. Oral compound — no reconstitution required.
Synergies & Common Stacks
5-Amino-1MQ preserves NAD+ precursors by blocking their methylation; NAD+ IV directly replenishes the pool. Together they maximize cellular NAD+ availability from both supply and demand sides.
MOTS-c activates AMPK mitochondrial signaling; 5-Amino-1MQ raises NAD+ which also activates SIRT1/AMPK. Complementary metabolic enhancement from different entry points.
GLP-1 agonist suppresses appetite/caloric intake; 5-Amino-1MQ may enhance lipolysis and metabolic rate via NNMT inhibition. Complementary mechanisms for body composition.
Dosing Quick Reference
Frequently Asked Questions
How does 5-Amino-1MQ differ from NMN for NAD+ optimization?▼
References
- Kannt A et al. “"NNMT inhibition rescues age-associated muscle atrophy".” Nature Communications (2018). PMID: 30552329
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code